Entocort CR 3mg capsules

Valsts: Lielbritānija

Valoda: angļu

Klimata pārmaiņas: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktīvā sastāvdaļa:

Budesonide

Pieejams no:

Lexon (UK) Ltd

ATĶ kods:

A07EA06

SNN (starptautisko nepatentēto nosaukumu):

Budesonide

Deva:

3mg

Zāļu forma:

Modified-release capsule

Ievadīšanas:

Oral

Klase:

No Controlled Drug Status

Receptes veids:

Valid as a prescribable product

Produktu pārskats:

BNF: 01050200

Lietošanas instrukcija

ENTOCORT CR 3MG CAPSULES / BUDECOL CR 3MG CAPSULES
(budesonide)
PATIENT INFORMATION LEAFLET
Your medicine is called Entocort CR 3mg Capsules/Budecol CR 3mg
Capsules, but will be referred to as Entocort Capsules.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE
BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU.
*
Keep this leaflet. You may need to read it again.
*
If you have any further questions, ask your doctor or pharmacist.
*
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their signs of illness are the same
as
yours.
*
If you get any side effects, talk to your doctor or pharmacist. This
includes
any possible side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
What Entocort Capsules are and what they are used for
What you need to know before you take Entocort Capsules
How to take Entocort Capsules
Possible side effects
How to store Entocort Capsules
Contents of the pack and other information
WHAT ENTOCORT CAPSULES ARE AND WHAT THEY ARE USED
FOR
Entocort Capsules contain the active substance budesonide. This
belongs to
a group of medicines called ‘corticosteroids’. These are used to
reduce
inflammation.
Crohn’s disease: Entocort Capsules are used to treat an inflammation
of the
small bowel and the first part of the large bowel.
Microscopic colitis: Entocort Capsules are used to treat microscopic
colitis
(a disease with chronic inflammation of the large bowel which is
typically
with chronic watery diarrhoea).
WHAT YOU NEED TO KNOW BEFORE YOU TAKE ENTOCORT
CAPSULES
DO NOT TAKE ENTOCORT CAPSULES:
*
If you are allergic to budesonide or any of the other ingredients of
this
medicine (listed in section 6).
*
If you have an infection.
Do not take Entocort Capsules if any of the above apply to you. If you
are
not sure, talk to your doctor or pharmacist before taking Entocort
Capsules.
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist before taking Entocort Capsules if:
*
You have ever had tuberculos

Produkta apraksts

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Entocort CR 3 mg Capsules
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains budesonide 3 mg
Excipient(s) with known effect:
Sucrose
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Hard gelatin capsules for oral administration with an opaque, light
grey body and
opaque, pink cap marked CIR
3MG in black radial print.
Each capsule contains budesonide 3 mg as gastro-resistant,
prolonged-release
granules.
4.1
THERAPEUTIC INDICATIONS
Crohn’s disease - Induction of remission in patients with mild to
moderate active
Crohn’s disease affecting the ileum and/or the ascending colon.
Microscopic colitis - Induction of remission in patients with active
microscopic colitis
Maintenance of remission in patients with microscopic colitis.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
POSOLOGY
ADULTS
_Active Crohn’s disease_: The recommended daily dose for induction
of remission is
9 mg once daily in the morning, for up to eight weeks. The full effect
is usually
achieved within 2–4 weeks.
When treatment is to be discontinued, the dose should normally be
reduced for the last
2 to 4 weeks of therapy.
_Active Microscopic colitis_: The recommended dose is 9 mg once daily
in the morning
(corresponding to 3 capsules).
_Maintenance of Microscopic colitis: _The recommended dose is 6 mg
once daily in the
morning (corresponding to 2 capsules), or the lowest effective dose.
_ _
_Paediatric population _
There are limited data on the use of Entocort CR Capsules in children
(see Sections
5.1 and 5.2). The available data are insufficient to support safety
and efficacy in the
paediatric population, therefore such use cannot be recommended until
further data
become available.
_Older people _
No special dose adjustment is recommended. However, experience with
Entocort CR
Capsules in older people is limited.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance(s) or to any of the
excipients listed in section
6.1.
4.4
SPECIAL WARNINGS